Lithobid
(Lithium)ApprovedSmall molecule
Lithium is used to treat bipolar disorder by helping to stabilize mood swings and reduce the severity of manic episodes. It can also be used to help prevent suicide in people with mood disorders.[2] Lithobid is currently approved and in use across 14 indications[4].[1]
Lithobid is one of 340 small molecule programs targeting Bipolar Depression. It is currently in Approved.
14
Indications
91
Total Trials
8
Active Trials
339
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
154 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Avastin
RochePhase 3
Vepesid
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bipolar Disorder20 trials
Show 17 more trials
Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder
Completed·—·Phase 3·NCT00221429·153 enrolled
Sequential Multiple Assignment Treatment for Bipolar Disorder
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT01588457·112 enrolled
Depression7 trials
Bipolar I Disorder4 trials
Treatment Resistant Depression4 trials
Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine
Withdrawn·—·Phase 2·NCT03290963
Show 1 more trial
40 more indications
Bipolar Depression3 trials
Major Depression3 trials
CAR2 trials
Fasting Conditions2 trials
Suicide2 trials
Cognitive impairment2 trials
Treatment2 trials
Amyotrophic Lateral Sclerosis1 trial
Phase 11 trial
First-line Treatment1 trial
Tics1 trial
Alzheimer's Disease1 trial
Effect of Lithium and Divalproex in Alzheimer's Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00088387·35 enrolled
Conduct Disorder1 trial
Long-Term Lithium Treatment for Aggressive Conduct Disorder
Completed·—·Phase 3·NCT00000385·59 enrolled
Major Depressive Disorder1 trial
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Recruiting·—·Phase 3·NCT05603104·1,254 enrolled
Parkinson's Disease1 trial
Progressive Supranuclear Palsy1 trial
Adult1 trial
Colorectal Cancer1 trial
Osteoporosis-Pseudoglioma Syndrome1 trial
Randomised Controlled Trial1 trial
Depressive Disorder1 trial
Olanzapine1 trial
Small Cell Lung Cancer1 trial
Aripiprazole1 trial
Maintenance Treatment1 trial
Huntington's Disease1 trial
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00095355·35 enrolled
Suicidality1 trial
Effectiveness1 trial
Mania1 trial
Unspecified5 trials
Lithium Versus Anticonvulsants and the Risk of Physical Disorders
Completed·—··NCT06005155·169,285 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
LITHIUM CITRATE
NDA NDA018421
Jan 1, 1982
LITHONATE
NDA NDA017672
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lithobid drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Lithium. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- SSolvay Pharmaceuticals